Relapsing-remitting multiple sclerosis

This study compares two versions of the drug ocrelizumab given as a shot under the skin in people with multiple sclerosis. The goal is to see if the new test version works the same as the current one. About 182 participants with relapsing or primary progressive MS will take part.

This study tests whether clemastine fumarate, a common allergy medicine, can help repair the protective coating around nerves (myelin) in people with multiple sclerosis. About 74 adults with relapsing-remitting MS will receive either the drug or a placebo, and advanced MRI scans …

This early-stage trial tests a new treatment called CC-97540, which uses a patient's own immune cells engineered to target and destroy harmful immune cells. The study includes 120 people with relapsing or progressive multiple sclerosis or refractory myasthenia gravis. The main go…

This phase 3 trial is testing whether a daily pill called remibrutinib works as well as the standard infusion or injection ocrelizumab for people with relapsing multiple sclerosis. About 360 adults aged 40–70 who are stable on ocrelizumab will either switch to remibrutinib or sta…

This study follows 30 adults in Taiwan with relapsing-remitting multiple sclerosis who are starting fingolimod (Gilenya), a daily pill that helps control the disease. Over 12 months, researchers will watch for specific side effects like slow heart rate, vision problems, liver iss…

This early-phase study tests whether combining mesenchymal stem cells (MSCs) with specially engineered immune cells (CAR-T cells) is safe and can help control autoimmune diseases. About 30 adults with established autoimmune conditions will receive the treatment and be monitored f…

This early-stage trial is testing a new way to give ocrelizumab (Ocrevus) for multiple sclerosis — as a simple shot under the skin instead of a long IV infusion. About 75 adults with MS will receive increasing doses to see if the new form is safe and tolerable. If it works, it co…

This study looks at whether people with early relapsing multiple sclerosis (MS) can stop taking ocrelizumab (Ocrevus) after two years without their disease coming back. All 123 participants will receive ocrelizumab for the first two years. Then, some will switch to a placebo whil…

This Phase 3 trial tests whether a simple injection of frexalimab every 4 weeks works as well as the standard IV infusion for adults with relapsing or non-active progressive multiple sclerosis. About 160 participants will be randomly assigned to one of the two methods. The study …

This study looks at whether people with relapsing-remitting multiple sclerosis (RRMS) who are over 40 and have been stable on strong anti-CD20 drugs for at least 3 years can safely switch to milder treatments. The goal is to see if this de-escalation approach prevents disease act…

This study tests whether specially engineered immune cells, called CAR-T cells, can safely treat autoimmune diseases. The cells are designed to target and suppress B cells, which play a key role in many autoimmune conditions. The trial involves 30 adults and focuses on safety and…

This study is testing a new blood filter called the Plasma Filter PX2. It is used in a procedure called therapeutic plasma exchange, which removes harmful substances from the blood of people with autoimmune diseases. About 46 adults will take part, and the study will check if the…

This early study tests a new treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders like multiple sclerosis and neuromyelitis optica. The treatment uses a patient's own immune cells that are modified in a lab to target and destr…

This Phase 3 trial is testing a modified dosing schedule of ublituximab (BRIUMVI) in 800 people with relapsing multiple sclerosis. The study has three parts: one open-label part to see if the new regimen reduces brain lesions, a placebo-controlled part to measure drug levels, and…

This Phase 2 trial tests an experimental mRNA therapy called mRNA-1195 in 180 adults aged 18 to 55 with relapsing multiple sclerosis. Participants receive either the mRNA shot or a placebo, and researchers monitor safety and measure new brain lesions on MRI scans over about 2.5 y…

This study tests an oral drug called fenebrutinib in 12 children and adolescents aged 10 to 17 with relapsing multiple sclerosis. The goal is to see how the drug moves through the body, how safe it is, and whether it reduces new brain lesions seen on MRI. Participants can choose …

This study tests a bone marrow transplant from a family donor for children under 21 with severe non-cancer blood disorders like sickle cell disease, bone marrow failure, or immune problems. The goal is to see if the transplant can replace the diseased cells with healthy donor cel…

This early-phase study tests an experimental cell therapy called YTB323 in about 28 people with relapsing multiple sclerosis whose disease is still active despite taking strong medications. The goal is to see if YTB323 is safe and can control the disease. Participants receive a s…

This study tests the drug ocrelizumab in 60 Chinese adults with two forms of multiple sclerosis (MS): relapsing MS and primary progressive MS. The goal is to see if it reduces relapses and controls disease activity. Participants receive ocrelizumab infusions, and researchers trac…

This early-stage trial is testing a new treatment called AZD0120 for people with multiple sclerosis (MS) that has not responded to other therapies. AZD0120 is a type of immune cell therapy (CAR-T) designed to target and reset the immune system. The study will enroll 24 adults age…

This study tests a small device implanted on the vagus nerve in the neck to see if it can help repair myelin (the protective coating around nerves) in people with relapsing-remitting multiple sclerosis. About 60 adults aged 22–50 will take part. Two-thirds will receive active sti…

This early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm the immune system in people with neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinat…

This study compares two daily pills, ozanimod and fingolimod, to see which works better at preventing MS relapses in children and teens aged 10 to 17. Participants will be randomly assigned to one of the two drugs and monitored for about two years. The goal is to find a more effe…

This early-stage study tests a new mRNA-based treatment (ABO2203) for people with autoimmune diseases that haven't improved with standard care. The therapy works by directing the body's immune cells to attack and control overactive immune cells causing the disease. The study will…

This study tests a drug called Ublituximab (Briumvi) given twice a year to people with early relapsing multiple sclerosis. Researchers want to see if it is safe and how it affects a nerve damage marker in the blood. About 40 adults with mild disability will take part for about on…

This early-phase study tests whether ublituximab, a drug for relapsing multiple sclerosis, can improve walking function and reduce fall risk. Twenty-five participants will receive the drug for 48 weeks, with walking, disability, and thinking tests before, during, and after treatm…

This phase 3 trial tests whether rituximab, a less expensive drug, works as well as ocrelizumab for people with relapsing-remitting multiple sclerosis. About 386 participants will receive either drug and be followed for 2 years. The main goal is to see if rituximab can keep the d…

This study tests whether a daily supplement of indole-3-propionic acid (IPA), a substance naturally made by gut bacteria, can help people with relapsing-remitting multiple sclerosis (RRMS). Over 27 months, 220 adults will take either IPA or a placebo. The main goal is to see if I…

This study is testing a supplement made from a broccoli compound (bioactivated GRA) in 300 people with Parkinson's disease, relapsing-remitting multiple sclerosis, or certain childhood nerve diseases. Participants will take the supplement daily for 6 months. Researchers will trac…

This study looks at how well the drug ofatumumab works and how safe it is for people with relapsing multiple sclerosis (RMS) in China. Researchers will measure a nerve damage marker called sNfL in the blood to see if the drug helps protect nerves. About 80 adults with RMS will ta…

This study compares a stem cell transplant (using a person's own cells) against the best available medications for people with relapsing multiple sclerosis that hasn't responded to treatment. About 156 participants will be randomly assigned to one of the two approaches and follow…

This study tests a new medicine called BCD-281 in people with relapsing-remitting multiple sclerosis (RRMS). The goal is to see if it reduces brain lesions and relapse rates better than the current standard drug. About 292 adults aged 18-55 with mild to moderate disability are be…

This study tests whether taking a daily probiotic supplement for six months can improve immune function in people with relapsing-remitting multiple sclerosis (MS). Eighty adults aged 18-55 will be randomly assigned to receive either the probiotic or a placebo, alongside their usu…

This study looks at whether people with stable relapsing multiple sclerosis can safely switch from anti-CD20 therapies (like rituximab or ocrelizumab) to ozanimod (Zeposia), an oral pill. About 100 participants who have had no new MS activity for at least two years will be follow…

This early-stage trial is testing a new cell therapy called GT719 in 30 adults with recurrent or hard-to-treat neurological autoimmune diseases. The goal is to see if it is safe and how long the cells last in the body. Researchers will also look for early signs that it might help…

This phase 1b trial is testing whether ixazomib, a drug already used for multiple myeloma, is safe for people with multiple sclerosis. The study will enroll 72 adults with relapsing-remitting or progressive MS. Participants will receive either ixazomib or a placebo for up to 24 m…

This study tests whether people with multiple sclerosis can learn to prevent falls by practicing on a treadmill that unexpectedly slips or trips. 64 participants aged 45 and older will be split into two groups: one gets the slip-and-trip training, the other just walks on the trea…

This study is testing whether the shingles vaccine (RZV) works and is safe for adults with autoimmune rheumatic diseases like rheumatoid arthritis or lupus who are taking immune-suppressing drugs. Two hundred participants will receive two doses of the vaccine. Researchers will me…

This study tests whether custom 3D-printed cutlery handles can help people with neurodegenerative diseases eat more independently. 75 patients in rehabilitation care will try handles in different sizes, designed to fit their grip. Researchers will measure changes in eating abilit…

This pilot study tests whether switching from ocrelizumab to ublituximab can reduce or delay the return of MS symptoms that some patients experience before their next scheduled infusion. Researchers will enroll 50 adults with relapsing MS who have been on ocrelizumab for at least…

This study tests a new 8-week program that combines motor imagery (mentally practicing movements) with vestibular rehabilitation (exercises for balance and dizziness) in 30 people with relapsing-remitting multiple sclerosis. The goal is to see if this combination improves balance…

This study tests whether a wearable device that gently vibrates arm muscles can improve arm and hand function in people with multiple sclerosis (MS). Fifteen adults with relapsing-remitting MS will use the device at home for 4 weeks. Researchers will measure dexterity, coordinati…

This study tests whether a mild electrical current applied to the front of the brain for 20 minutes a day over five days can reduce central fatigue in people with relapsing-remitting multiple sclerosis. Researchers will use brain scans and blood tests to see if the stimulation ch…

This study tests whether a gentle magnetic pulse to a specific brain area can reduce fatigue in people with multiple sclerosis. Sixty participants will receive either real or fake stimulation for 30 minutes daily over five days. Researchers will track changes in fatigue, brain ch…

This study tests a home-based balance training program for people with multiple sclerosis (MS). The program combines stepping games, strength, and thinking tasks. Researchers will compare it to a simple stretching routine in 75 adults with MS to see if it improves physical functi…

This study tests a wearable device called the Cionic Neural Sleeve that uses mild electrical pulses to help leg muscles contract at the right time during walking. Fourteen people with multiple sclerosis will wear the sleeve for six weeks and also do a walking program. Researchers…

This study is looking for the genes that cause certain immune system problems. Researchers want to understand why some people get sick and others don't, even in the same family. Up to 5,000 people with immune disorders and their relatives will give blood or cheek cell samples for…

This study will analyze DNA from up to 20,000 people, including those with immune disorders and their relatives, to find genetic variants linked to conditions like atopy, autoimmunity, and primary immunodeficiency. Researchers will also study how best to return genetic results to…

This observational study is recruiting 2400 people with immune-related central nervous system diseases, such as multiple sclerosis, along with healthy volunteers for comparison. Researchers will use MRI scans, lumbar punctures, blood tests, and neurological exams to track disease…

This study aims to learn more about how diseases related to blood clots, the immune system, and blood vessels start and change over time. Researchers will enroll up to 1,000 people aged 5 and older, including those with these conditions, their healthy relatives, and healthy volun…

This study is measuring a protein called STIM1 on the surface of immune cells in 670 people with various autoimmune diseases. The goal is to find which diseases have high levels of this protein, which could help researchers develop new antibody-based treatments. Participants prov…

This study looks for better ways to detect lung inflammation and infections early in people who have received a stem cell transplant from a donor. About 40 participants aged 5 to 70 will get regular lung scans, breathing tests, blood draws, and a procedure where a tube collects f…

This study is testing whether monthly blood tests for a nerve damage marker (neurofilament light chain) can detect hidden disease activity in people with relapsing-remitting multiple sclerosis (MS) earlier than standard yearly MRI scans. The goal is to reduce the need for gadolin…

This registry study will follow 2000 people with relapsing multiple sclerosis who are prescribed BRIUMVI (ublituximab-xiiy) in real-world settings. Researchers aim to track safety, effectiveness (like relapse rates), and the overall treatment experience. Participants must not hav…

This study looks at how much of the multiple sclerosis drug BRIUMVI gets into breast milk. About 16 breastfeeding women with relapsing MS will provide milk samples after their regular treatment. The goal is to understand drug exposure for nursing infants, not to test a new treatm…

This study examines how spinal posture and movement relate to balance in 30 adults with relapsing-remitting multiple sclerosis. Researchers will measure spinal angles and mobility, then compare them with balance tests. The goal is to identify links that could inform future rehabi…

This study follows 160 people with relapsing multiple sclerosis in Greece who are already taking ofatumumab (Kesimpta®) as part of their routine care. Researchers will track how many patients have no signs of disease activity—like relapses, new brain lesions, or worsening disabil…

This study tests a new type of MRI that looks at energy use in the brain to see if it can predict how well multiple sclerosis (MS) patients will respond to a common therapy. Researchers will scan 40 adults with relapsing-remitting MS before and after they start treatment. The goa…

This study is not testing a new drug. Instead, it will observe 800 people with relapsing multiple sclerosis in Germany who are already taking approved injectable or oral medications. Researchers will track how long patients stick with their prescribed treatment over up to four ye…

This study looks at whether a new eye-tracking device can help doctors see how well multiple sclerosis (MS) treatment is working. About 224 Canadian adults with relapsing-remitting MS will use the device during routine care. The goal is to find out if eye movement changes can rep…

This study looks at how difficult childhood experiences might impact the course of multiple sclerosis (MS). Researchers will work with 300 young adults with relapsing-remitting MS, focusing on Black, Hispanic, and low-income groups often left out of research. Participants will ha…

This study will test whether a special eye scan (OCT) can detect changes in the retina that show how well the MS drug ublituximab is working. Researchers will compare 15 people starting ublituximab with 15 people on other MS treatments. The goal is to find a new, non-invasive way…

This observational study at Washington University will use special PET scans to look at ongoing inflammation in the brains of 25 people with relapsing-remitting multiple sclerosis. Researchers want to understand why inflammation persists even after standard treatment. Participant…

This study collects and freezes testicular tissue from boys and young men who are at risk of becoming infertile due to cancer, autoimmune disorders, or their treatments. The tissue is stored in a research bank, with the hope that future medical advances will allow it to be used t…

This study looks at how multiple sclerosis affects the autonomic nervous system, which controls automatic body functions like heart rate and sweating. Researchers will use skin biopsies and heart tests to measure nerve damage in 60 people with relapsing-remitting or primary progr…

This study looks at people with brain damage from strokes, tumors, or other conditions to understand why they have specific thinking problems. Researchers will use brain scans and cognitive tests to link brain areas to deficits. The goal is to learn more about how the brain works…

This study is testing a tool called B-COMPASS that uses a 22-question survey to predict whether people will follow their prescribed treatments. Researchers will enroll 3100 adults with cardiovascular, endocrine, immune, nerve, cancer, or rare diseases across Europe. The goal is t…

This study tests whether breathing short bursts of low-oxygen air (like at high altitude) can improve ankle strength and brain activity in people with multiple sclerosis. Twenty-one adults with relapsing forms of MS will undergo 15 cycles of low oxygen followed by normal air in o…

This study collects blood samples from 1000 people with rare neurological diseases that may be autoimmune. Researchers will use the samples to find new biomarkers and autoantibodies, which could help diagnose and treat these conditions in the future. Participants give extra blood…

This study gathers medical information from 200 adults with possible nerve, muscle, or autonomic nervous system disorders who are not already in other NIH studies. Participants undergo standard tests like nerve conduction studies, EMG, and physical exams. The data is stored anony…

This study uses a special PET-MRI scan to measure brain inflammation in people with multiple sclerosis (MS). Researchers will scan 41 adults with active MS and compare the results to healthy volunteers. The goal is to better understand inflammation patterns and improve how we pre…

This study looks at how sleep issues contribute to tiredness and thinking problems in people with multiple sclerosis (MS). About 382 MS patients and a control group without MS will have overnight sleep tests, thinking assessments, and questionnaires. The goal is to better underst…

This study looks at 320 adults who are about to start strong immune-suppressing therapy and have already had at least two COVID-19 shots. Researchers want to find out if giving a COVID-19 booster right before starting therapy or waiting six months provides better protection. Part…

This study tests whether a breathing technique called Acute Intermittent Hypoxia (AIH) can help improve arm and hand function in people with multiple sclerosis (MS). Participants will breathe short bursts of low-oxygen air while researchers measure brain signals and muscle streng…

This study is creating a large registry of 800 people receiving biologic medications for immune conditions like autoimmune diseases and primary immune deficiencies. Researchers will collect blood samples and health data to better understand how these treatments work and who respo…

This study uses special PET scans to look for brain inflammation in people with multiple sclerosis (MS) and Alzheimer's disease. Researchers will compare two radioactive tracers, [F-18]PBR06 and [C-11]PBR28, to see which works better. Up to 250 participants, including healthy vol…

This study tests a digital platform that combines an app for patients and a brain-scan analysis tool for doctors. The goal is to see if it helps monitor multiple sclerosis (MS) more easily in everyday care. About 500 people with relapsing-remitting MS will use the app and have th…

This study looks at how the brain uses sugar (glucose) in people with multiple sclerosis (MS) compared to healthy volunteers. Researchers will use a special PET scan to measure brain activity and compare it with MRI scans and blood tests. The goal is to find better ways to diagno…

This study tests whether a short burst of aerobic exercise on a stationary bike and a 30-minute nap can improve how people with multiple sclerosis learn and remember a hand motor skill. Twenty adults with relapsing-remitting MS will take part. Researchers will measure brain and m…

This observational study looks at how gut bacteria relate to brain structure and function in healthy aging and in people with early Alzheimer's, Parkinson's, or multiple sclerosis. Researchers will use brain scans, stool samples, blood tests, and cognitive assessments in 200 part…

This study aims to understand how brain connections (synapses) are lost in progressive multiple sclerosis (MS). Researchers will use a new type of PET scan to measure synaptic density in 30 people with progressive MS, relapsing-remitting MS, and healthy volunteers. The goal is to…

This study looks at two ways to treat multiple sclerosis (MS) when it first appears after age 50. One approach starts with a moderate-strength drug and only switches to a stronger one if needed. The other starts with a strong drug right away. Researchers will compare how often re…

This study is collecting health data, smartphone app measurements, and biological samples from 100 people with multiple sclerosis. Researchers aim to find new biomarkers and digital tools to better understand how MS progresses and when it changes form. The goal is to improve moni…

This study is looking at how people with conditions like schizophrenia, bipolar disorder, depression, and neurological diseases (such as Alzheimer's or stroke) perform on computer-based thinking tests. The goal is to create a detailed map of cognitive strengths and weaknesses acr…

This study looks at whether using a swallow gel or a semi-solid vehicle can help people with neurological conditions swallow pills more easily and safely. Researchers will observe 500 participants, including patients with swallowing disorders and healthy volunteers, as they swall…

This study looks at how well therapeutic plasma exchange (a blood-filtering procedure) works for people with autoimmune neurological diseases. Researchers at Al-Azhar University Hospitals will follow 60 Egyptian patients to see if their symptoms and daily function improve. The go…

This study looks at whether short selfie videos taken on a phone can accurately measure walking and speech changes in people with multiple sclerosis (MS). About 300 adults with MS will record 5 videos every 3 months for a year and also attend some in-person visits. The goal is to…

This study aims to find out how often sexual dysfunction occurs in women with relapsing-remitting multiple sclerosis and how it connects to fatigue, depression, anxiety, overactive bladder, and thinking problems. Researchers will use questionnaires and tests to measure these fact…

This study follows 400 people with relapsing-remitting multiple sclerosis to see how their brains change over three years. Researchers will use MRI scans and blood tests to compare those on high-efficacy treatments versus medium-efficacy ones. The goal is to understand which trea…

This study follows 100 people with relapsing-remitting multiple sclerosis who are taking anti-CD20 drugs like ofatumumab or rituximab. Researchers will track changes in immune cells, proteins, and brain scans over time to understand how these therapies work long-term. The goal is…